Novel vaccine candidate for Staphylococcus aureus shows 80% efficacy in mice


Published today in Infection and Immunity, researchers have identified a novel vaccine for Staphylococcus aureus, which has demonstrated 80% efficacy in mouse and rabbit models.

Hospital-acquired S. aureus infections result in 30,000 deaths annually, with an upper mortality rate of approximately 30%, in cases of bacteremia. With over 70 virulence factors and rapid biofilm formation, S. aureus is highly resistant to the host immune response as well as many antibiotics.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.



Leave A Comment